pioglitazone has been researched along with Anemia in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease." | 9.14 | Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010) |
| "Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease." | 5.14 | Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010) |
| "To investigate the recovery of thiazolidinedione-induced body weight gain and haematopoietic changes after stopping pioglitazone treatment in patients with Type 2 diabetes." | 3.80 | Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes. ( Chen, BK; Feng, CC; Lee, MY; Lin, KD; Shin, SJ; Yu, ML, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, KD | 1 |
| Lee, MY | 1 |
| Feng, CC | 1 |
| Chen, BK | 1 |
| Yu, ML | 1 |
| Shin, SJ | 1 |
| Barthel, A | 1 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Soma, M | 1 |
| Matsumoto, K | 1 |
1 trial available for pioglitazone and Anemia
| Article | Year |
|---|---|
Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
Topics: Adiponectin; Adult; Aged; Anemia; Blood Pressure; C-Reactive Protein; Calcitriol; Diabetes Mellitus, | 2010 |
2 other studies available for pioglitazone and Anemia
| Article | Year |
|---|---|
Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
Topics: Aged; Anemia; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Drug Monitoring; Erythrocy | 2014 |
[Is Pioglitazone blessing or curse?].
Topics: Anemia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Th | 2016 |